Key result
PTX3 knockout attenuates Ang II-induced cardiac hypertrophy, fibrosis, and inflammation in mice.
Why the study?
This study investigated the functional involvement of PTX3 in Ang II-mediated cardiac hypertrophy pathogenesis, focusing on its potential regulation through inflammatory pathways and oxidative stress mechanisms.
Does genetic ablation of PTX3 prevent Angiotensin II-induced cardiac hypertrophy, inflammation, and oxidative stress in mice?
Does genetic ablation of PTX3 prevent Angiotensin II-induced cardiac hypertrophy, inflammation, and oxidative stress in mice?
Genetic ablation of PTX3 protects against Angiotensin II-induced cardiac hypertrophy, fibrosis, inflammation, and oxidative stress in mice, suggesting PTX3 as a potential therapeutic target for hypertrophic cardiomyopathy.
Supports PTX3 as target in Ang II cardiac remodeling; hypothesis-generating and requires human validation before any practice change.
Pentraxin 3 (PTX3) responds rapidly to inflammatory signals. This study investigated the functional involvement of PTX3 in angiotensin II (Ang II)-mediated cardiac hypertrophy pathogenesis, with particular focus on its potential regulation through inflammatory pathways and oxidative stress mechanisms. In vivo, chronic Ang II infusion over 4 weeks was used to induce hypertrophic cardiomyopathy in mice. In parallel, an in vitro model of cardiomyocyte hypertrophy was established by treating neonatal rat cardiomyocytes (NRCMs) with Ang II for 24 h. Ang II treatment significantly increased PTX3 expression, an effect observed in both mouse heart tissue and NRCMs. The cardiac hypertrophy and fibrosis in mice treated with Ang II were alleviated by PTX3 knockout. Genetic ablation of PTX3 attenuated Ang II-induced upregulation of cardiac hypertrophy markers in mice hearts, including atrial natriuretic peptide, brain natriuretic peptide, and beta-myosin heavy chain. Additionally, PTX3 knockout suppressed the elevation of pro-inflammatory cytokines, including tumour necrosis factor-alpha and interleukin-1beta, following Ang II stimulation. Genetic deficiency of PTX3 significantly ameliorated cardiac oxidative stress potentiated by Ang II infusion. These outcomes showed that targeting of PTX3 could ameliorate hypertrophic cardiomyopathy via attenuation of inflammatory response and oxidative stress. PTX3 may be a target for therapy of hypertrophic cardiomyopathy in the future.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) studied Angiotensin II-induced cardiac hypertrophy. PTX3 knockout vs. Wild-type mice was evaluated on Cardiac hypertrophy, fibrosis, inflammation, and oxidative stress markers. Genetic ablation of PTX3 alleviated Angiotensin II-induced cardiac hypertrophy, fibrosis, inflammation, and oxidative stress in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: